LifeSci Acquisition II Corp. (LSAQ)
| Market Cap | 100.01M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 10.01M |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,054 |
| Open | 9.98 |
| Previous Close | 9.99 |
| Day's Range | 9.97 - 9.98 |
| 52-Week Range | 9.76 - 12.68 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | n/a |
About LSAQ
LifeSci Acquisition II Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities in the healthcare industry. The company was incorporated in 2019 and is based in New York, New York.
News
LifeSci Acquisition II Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Busi...
NEW YORK, June 16, 2021 (GLOBE NEWSWIRE) -- LifeSci Acquisition II Corp. (NASDAQ: LSAQ), a blank check company formed for the purpose of pursuing targets that are focused on healthcare innovation, today...
'SPACs Attack' Recap: Looking Back At 5 SPAC Deals, Rumors And Top Headlines
Last week featured five announced SPAC deals and several rumors. The week also had earnings from several well-known former SPACs.
Science 37 Taps SPAC For NASDAQ Listing Valued At Around $1B
Science 37, a life science company, is tapping the craze of a special purpose acquisition company to help it with a major public listing. Specifically, its is penning a merger agreement with LifeSci Acq...
Science 37 to Become Publicly Listed via Merger with LifeSci Acquisition II Corp., Powering the Clinical Trial Operat...
LOS ANGELES & NEW YORK--(BUSINESS WIRE)-- #IPOs--Science 37, Inc. and LifeSci Acquisition II Corp announced that they have entered into a definitive business combination agreement.
LifeSci Acquisition II Corp. Announces Pricing of $75 Million Initial Public Offering
NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) -- LifeSci Acquisition II Corp. (NASDAQ: LSAQ), a blank check company targeting the biopharma sector, announced today that it priced its initial public offering ...